Savara (NASDAQ:SVRA) Stock Price Up 5.9%

Savara Inc (NASDAQ:SVRA)’s stock price traded up 5.9% during trading on Tuesday . The company traded as high as $5.25 and last traded at $5.24. 808,375 shares changed hands during trading, a decline of 6% from the average session volume of 863,845 shares. The stock had previously closed at $4.95.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Piper Sandler upped their target price on shares of Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. JMP Securities reiterated a “market outperform” rating and set a $8.00 price objective on shares of Savara in a report on Monday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $8.20.

Savara Price Performance

The business has a fifty day moving average of $4.90 and a two-hundred day moving average of $4.50. The firm has a market capitalization of $726.83 million, a price-to-earnings ratio of -15.00 and a beta of 0.73. The company has a debt-to-equity ratio of 0.19, a quick ratio of 15.66 and a current ratio of 15.66.

Savara (NASDAQ:SVRA) last posted its earnings results on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. As a group, research analysts predict that Savara Inc will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

A number of hedge funds have recently bought and sold shares of the business. AJOVista LLC acquired a new position in shares of Savara during the 4th quarter worth approximately $40,000. Principal Financial Group Inc. acquired a new stake in Savara during the third quarter worth approximately $48,000. China Universal Asset Management Co. Ltd. acquired a new stake in Savara during the fourth quarter worth approximately $74,000. Kestra Private Wealth Services LLC bought a new position in Savara during the 3rd quarter worth $64,000. Finally, Tower Research Capital LLC TRC raised its holdings in Savara by 665.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock valued at $92,000 after acquiring an additional 16,959 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.